SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Biotechnology

Healthcare
$29.68 +2.49%

+$0.45 today

Market cap
$993.14M
Beta
-0.34
P/E (TTM)
-14.1
EPS (TTM)
-$1.32
52W Low $17.06High $32.44

Volume 0.10M

Average 0.09M

SGP Net Income

Bottom-line profit after all expenses, interest, and taxes.

SpyGlass Pharma, Inc. Common StockNASDAQ: SGP

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income of -$13.82M in Q1 FY2026

Q1 FY2026 net income was -$13.82M.

What to watch

Whether net income reaches the consensus estimate of -$76.01M (-90.7%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.82M-10.1% QoQ
Last fiscal yearDec 2025
-$39.87M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—-90.7%—
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(39.87M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SGP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
SGP Competitors
Net Income for SGP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALCAlcon Inc.LTM Sep 2026$662.33M USD-36.7%+43.0%6.1%
STAASTAAR Surgical CompanyLTM Apr 2026-$21.03M USD+70.4%—7.2%
SGHTSight Sciences, Inc.LTM Mar 2026-$37.25M USD+24.6%—46.8%
SGPSpyGlass Pharma, Inc. Common StockFY2025-$39.87M USD———
RXSTRxSight, Inc.LTM Mar 2026-$46.64M USD-75.7%—36.6%
OCSOculis Holding AGLTM Mar 2026-CHF 95.06M CHF+7.6%—18861.3%
BLCOBausch + Lomb CorporationLTM Jun 2026-$171M USD+37.4%—3.2%
GKOSGlaukos CorporationLTM Jun 2026-$188.05M USD-102.7%—30.7%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$271.6M USD-85.0%—3566.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$290.5M USD-50.7%—558.2%
Peer median (excluding SGP) —-36.7%+43.0%36.6%

Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.